

Sponsored by

# Diaceutics

Better Testing, Better Treatment®

## Addressing the Economic and Operational Issues of the Clinical Practice Gaps in NSCLC

This paper identifies critical barriers and proposes actionable strategies to enhance precision medicine access for Non-Small Cell Lung Cancer (NSCLC) patients.

### BACKGROUND

In 2022, Diaceutics' globally recognized publication "The Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer" was published in The Journal of Clinical Oncology Precision Oncology (JCO). This research identified 7 Clinical Practice Gaps limiting patient access to precision medicine, and revealed that a shocking 64.4% of patients did not receive the optimal precision medicine treatment for them.

### THE FORUM

In reaction to this finding, an interdisciplinary group of experts known as 'The Precision Medicine Practice Gaps Economic, Policy and Operational Solutions Forum' was established in August 2023. The aim of The Forum was to urgently address the economic and operational barriers currently preventing patients gaining access to the optimal precision medicine treatments, and to provide the industry and policy makers with valuable and clear economic guidance and recommendations to overcome these challenges obstructing the advancement of precision medicine.

### THE SUMMIT

The solutions and recommendations proposed by the Forum were shared and opened for discussion at a virtual global Summit in May 2024, and broadcast live from Diaceutics' headquarters in Belfast. The Summit attracted over 400 registrants from various sectors, including pharma, academia, clinical research, diagnostics, labs, payers, policy, and patient advocacy groups. Following the Summit, the Forum refined these recommendations into clear, actionable guidelines. These final recommendations, now presented in this white paper, aim to provide industry and policy makers with valuable and clear economic guidance and recommendations to overcome the challenges obstructing the advancement of precision medicine.

**64.4%**

of patients are unable to access optimal precision medicine treatments due to economic and operational barriers.

August 2023: The Precision Medicine Practice Gaps Forum was established to tackle these issues.



**400+**

registrants from sectors like pharma, academia, clinical research, and advocacy joined a global virtual solutions.

2022: Diaceutics published the Clinical Practice Gaps paper in JCO, highlighting these barriers.



4 virtual workshops held over 10 months to address real-world barriers in NSCLC.



# The Five Key Recommendations



## Integration of precision oncology approach

Urgently integrate a precision oncology approach in the clinical care pathway within healthcare providers. Incentivize physicians through quality metrics, impact analysis and best practice examples.



## Implementation of reflex testing at earlier disease stage

Develop a value-based evidence framework for appropriate precision medicine testing earlier in the patient journey, empowering pathologists to enable reflex testing to inform treatment decisions and improve patient outcomes.



## Redesign of precision medicine clinical guideline generation

Undertake a fundamental redesign of precision medicine clinical guidelines to better accommodate the rapid evolution of technology and disease understanding.



## Transition to a sustainable dual system reimbursement

Create tiers for medically necessary and recommended for optimal care. Payers could be requested to cover what is medically necessary today, while additional sponsorship could be utilized for bridging the gap with tests for optimal care.



## Inclusion of diverse voices in policy and guideline development

Further advocate for the inclusion of patient advocacy groups, underserved populations, pathologists, genetic counselors, pharmacists, nurses and other healthcare professionals in policy and guideline development process.



## Impact and Future Vision

By implementing these recommendations, we aim to foster a more inclusive and data-driven healthcare landscape, ultimately improving patient outcomes and ensuring equitable access to precision medicine.

# The Forum

## Co-chaired by



**Susanne Munksted**  
Chief Precision Medicine Officer,  
Diaceutics



**Denny Van Liew**  
Life Sciences Senior Advisor,  
Red Nucleus



**Prof. Gerardine Doyle**  
Full Professor of Accounting,  
University College Dublin  
Visiting Scholar,  
Harvard University



**Sarah Hersey**  
VP, Head of Precision Medicine  
Bristol-Myers Squibb



**Amy Gorman**  
Global Precision Medicine & Diagnostics  
Commercial Leader  
AbbVie



**Cecilia Schott**  
Vice President, Precision Medicine Portfolio  
Planning at GSK  
Novartis Chair  
Precision Cancer Consortium



**Brenda Yanak**  
Founder  
Clinical Transformation Partners



**Dr. Daryl Pritchard**  
Senior Vice President of Science Policy  
Personalized Medicine Coalition



**Peter Keeling**  
Founder  
Diaceutics



**Dr. Kamala Maddali**  
Advisory Board member  
ConcertAI  
President  
Health Collaborations



**Terri Conneran**  
Founder  
KRAS KICKERS  
Survivor of KRAS G12D lung cancer



**Prof. Mark Lawler**  
Chair in Translational Cancer Genomics  
Queen's University Belfast



**Dr. Pranil Chandra**  
Senior Vice President and Chief Genomics Officer  
Pathgroup



**Dawn Cardeiro**  
Director of Precision Medicine  
Point32Health\*  
\*The views and opinions expressed by Ms. Cardeiro are hers and do not necessarily reflect those of Point32Health.



**Sibylle Lenz**  
Head of Precision Medicine and Vice President  
Merck & Co., Inc.

To explore these recommendations in more detail download the recommendations paper today. Contact us for more information on how we are progressing these recommendations.



<https://lp.diaceutics.com/econpaper/>



@Diaceutics



@diaceutics